Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea Stepping Up IO R&D To Catch Up With Global Players, Trends

Executive Summary

Immuno-oncology deals and R&D by South Korean companies are picking up speed as they are put more focus on the hot sector in line with global trends.

Advertisement

Related Content

Oncology, Diabetes Dominate Korean Out-Licensing But Deals And Value Decline
What Does 2018 Hold For Biopharma?
Genexine Seals I-O Licensing Deal With I-Mab, Builds Momentum
ViroMed Steps Up Global Ambitions With New Gene Therapy Pipeline
ImmuneOncia: A PD-L1 Latecomer Hoping To Break Into The Market
Chinese API Maker Huahai Leaps Into IO Via Korean Startup
AbbVie Picks Up Dong-A Candidate As It Makes Immuno-Onc Inroads

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100215

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel